BerGenBio to Present at DNB Nordic Healthcare Conference
Bergen, Norway, December 12, 2022 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced that Martin Olin, Chief Executive Officer of BerGenBio, will present at the 14th Annual DNB Nordic Healthcare Conference in Oslo, Norway, on Thursday, December 14, 2023, at 12:35pm CET. The presentation will be made available on the Company website in the presentations section on the day of the event: www.bergenbio.com/investors/presentations/ -End- Contacts